|MDACC Study No:||2012-0188 (clinicaltrials.gov NCT No: NCT01729104)|
|Title:||A Phase I/II Study of Carfilzomib plus Lenalidomide and Rituximab in the Treatment of relapsed/refractory Mantle Cell Lymphoma|
|Principal Investigator:||Michael Wang|
|Treatment Agent:||Carfilzomib; Lenalidomide; Rituximab|
|Study Description:||The goal of Part 1 of this clinical research study is to find the highest |
tolerable dose of carfilzomib that can be given in combination with
lenalidomide and rituximab to patients with relapsed or refractory B-cell
The goal of Part 2 of this study is to learn if the drug combination can help
to control B-cell non-hodgkin lymphoma.
The safety of this drug combination will be studied in both parts.
Carfilzomib is designed to keep cancer cells from repairing themselves. If the
cancer cells cannot repair themselves, this may cause them to die.
Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells.
Rituximab is designed to attach to cancer cells and damage them, which may
cause the cancer cells to die. It is also designed to cause the immune system
to attack cancer cells.